Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results, Beats Expectations By $0.04 EPS

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.04, Zacks reports. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. Aurinia Pharmaceuticals updated its FY 2025 guidance to EPS.

Aurinia Pharmaceuticals Trading Down 4.7 %

NASDAQ AUPH traded down $0.38 on Thursday, hitting $7.58. 3,408,142 shares of the company were exchanged, compared to its average volume of 1,322,935. The firm has a market capitalization of $1.08 billion, a P/E ratio of -50.36 and a beta of 1.22. Aurinia Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $10.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The company’s 50 day moving average price is $8.22 and its 200-day moving average price is $7.77.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.